Online inquiry

IVTScrip™ mRNA-Anti-VEGFA, 12-IgG1(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ187MR)

This product GTTS-WQ187MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets VEGFA gene. The antibody can be applied in Cancers, non-small cell lung (NSCLC), Coat's disease research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_001025366.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 7422
UniProt ID P15692
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-VEGFA, 12-IgG1(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ187MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ7933MR IVTScrip™ mRNA-Anti-ICOS, GSK-3359609(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA GSK-3359609
GTTS-WQ15890MR IVTScrip™ mRNA-Anti-SLC34A2, XMT-1536(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA XMT-1536
GTTS-WQ4931MR IVTScrip™ mRNA-Anti-GP, c13C6-FR1-N(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA c13C6-FR1-N
GTTS-WQ1946MR IVTScrip™ mRNA-Anti-SLITRK6, AGS15C(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA AGS15C
GTTS-WQ12340MR IVTScrip™ mRNA-Anti-TIGIT, MTIG-7192-A(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA MTIG-7192-A
GTTS-WQ3186MR IVTScrip™ mRNA-Anti-ANPEP, ARENEGYR(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA ARENEGYR
GTTS-WQ1960MR IVTScrip™ mRNA-Anti-SLITRK6, AGS-15E(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA AGS-15E
GTTS-WQ12479MR IVTScrip™ mRNA-Anti-IL20, NN-8226(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA NN-8226
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW